APO Research
Talk to an analyst

APO RESEARCH · REPORT

Women’s Health Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Women’s Health Drugs Market Outlook and Growth Opportunities 2026

31 December 2025194 pages

Choose your research edition.

Industry ResearchWomen’s Health Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Women’s Health Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Women’s Health Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Women’s Health Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Women’s Health Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Women’s Health Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Women’s Health Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Women’s Health Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Women’s Health Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Women’s Health Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Women’s Health Drugs market include Johnson & Johnson, Novartis AG, Merck & Co, Mylan N.V., Pfizer Inc, Bayer AG, Amgen, Lupin (India) and Ferring Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Women’s Health Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Women’s Health Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Women’s Health Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Women’s Health Drugs market.

Women’s Health Drugs Segment by Company

Johnson & Johnson

Novartis AG

Merck & Co

Mylan N.V.

Pfizer Inc

Bayer AG

Amgen

Lupin (India)

Ferring Pharmaceuticals

Eli Lilly And Company

Allergan

Agile Therapeutics Inc

Women’s Health Drugs Segment by Type

Minastrin 24 Fe

XGEVA

Prolia

Mirena

EVISTA

Zometa

Reclast/Aclasta

Others (Premarin, ACTONEL, ORTHO TRI-CY LO)

Women’s Health Drugs Segment by Application

Contraceptives

Polycystic Ovary Syndrome

Hormonal Infertility

Menopause

Postmenopausal Osteoporosis

Endometriosis

Other Applications

Women’s Health Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Women’s Health Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Women’s Health Drugs key companies, revenue, market share, and recent developments.

3. To split the Women’s Health Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Women’s Health Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Women’s Health Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Women’s Health Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Women’s Health Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Women’s Health Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Women’s Health Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Women’s Health Drugs industry.

Chapter 3: Detailed analysis of Women’s Health Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Women’s Health Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Women’s Health Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Women’s Health Drugs Industry Trends Table 2. Women’s Health Drugs Industry Drivers Table 3. Women’s Health Drugs Industry Opportunities and Challenges Table 4. Women’s Health Drugs Industry Restraints Table 5. Global Women’s Health Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Women’s Health Drugs Revenue Share by Company (2021-2026) Table 7. Global Women’s Health Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Women’s Health Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Women’s Health Drugs Company, Product Type & Application Table 10. Global Women’s Health Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Women’s Health Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Minastrin 24 Fe Table 15. Significant Companies of XGEVA Table 16. Significant Companies of Prolia Table 17. Significant Companies of Mirena Table 18. Significant Companies of EVISTA Table 19. Significant Companies of Zometa Table 20. Significant Companies of Reclast/Aclasta Table 21. Significant Companies of Others (Premarin, ACTONEL, ORTHO TRI-CY LO) Table 22. Global Women’s Health Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 23. Global Women’s Health Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 24. Global Women’s Health Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 25. Global Women’s Health Drugs Sales Value Share by Type (2021-2026) Table 26. Global Women’s Health Drugs Sales Value Share by Type (2027-2032) Table 27. Significant Companies of Contraceptives Table 28. Significant Companies of Polycystic Ovary Syndrome Table 29. Significant Companies of Hormonal Infertility Table 30. Significant Companies of Menopause Table 31. Significant Companies of Postmenopausal Osteoporosis Table 32. Significant Companies of Endometriosis Table 33. Significant Companies of Other Applications Table 34. Global Women’s Health Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Women’s Health Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 36. Global Women’s Health Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 37. Global Women’s Health Drugs Sales Value Share by Application (2021-2026) Table 38. Global Women’s Health Drugs Sales Value Share by Application (2027-2032) Table 39. Global Women’s Health Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Women’s Health Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 41. Global Women’s Health Drugs Sales Value Share by Region (2021-2026) Table 42. Global Women’s Health Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 43. Global Women’s Health Drugs Sales Value Share by Region (2027-2032) Table 44. Global Women’s Health Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Women’s Health Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 46. Global Women’s Health Drugs Sales Value Market Share by Country (2021-2026) Table 47. Global Women’s Health Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 48. Global Women’s Health Drugs Sales Value Market Share by Country (2027-2032) Table 49. Johnson & Johnson Company Information Table 50. Johnson & Johnson Business Overview Table 51. Johnson & Johnson Women’s Health Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Johnson & Johnson Women’s Health Drugs Product Portfolio Table 53. Johnson & Johnson Recent Development Table 54. Novartis AG Company Information Table 55. Novartis AG Business Overview Table 56. Novartis AG Women’s Health Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Novartis AG Women’s Health Drugs Product Portfolio Table 58. Novartis AG Recent Development Table 59. Merck & Co Company Information Table 60. Merck & Co Business Overview Table 61. Merck & Co Women’s Health Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Merck & Co Women’s Health Drugs Product Portfolio Table 63. Merck & Co Recent Development Table 64. Mylan N.V. Company Information Table 65. Mylan N.V. Business Overview Table 66. Mylan N.V. Women’s Health Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Mylan N.V. Women’s Health Drugs Product Portfolio Table 68. Mylan N.V. Recent Development Table 69. Pfizer Inc Company Information Table 70. Pfizer Inc Business Overview Table 71. Pfizer Inc Women’s Health Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Pfizer Inc Women’s Health Drugs Product Portfolio Table 73. Pfizer Inc Recent Development Table 74. Bayer AG Company Information Table 75. Bayer AG Business Overview Table 76. Bayer AG Women’s Health Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bayer AG Women’s Health Drugs Product Portfolio Table 78. Bayer AG Recent Development Table 79. Amgen Company Information Table 80. Amgen Business Overview Table 81. Amgen Women’s Health Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Amgen Women’s Health Drugs Product Portfolio Table 83. Amgen Recent Development Table 84. Lupin (India) Company Information Table 85. Lupin (India) Business Overview Table 86. Lupin (India) Women’s Health Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Lupin (India) Women’s Health Drugs Product Portfolio Table 88. Lupin (India) Recent Development Table 89. Ferring Pharmaceuticals Company Information Table 90. Ferring Pharmaceuticals Business Overview Table 91. Ferring Pharmaceuticals Women’s Health Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Ferring Pharmaceuticals Women’s Health Drugs Product Portfolio Table 93. Ferring Pharmaceuticals Recent Development Table 94. Eli Lilly And Company Company Information Table 95. Eli Lilly And Company Business Overview Table 96. Eli Lilly And Company Women’s Health Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Eli Lilly And Company Women’s Health Drugs Product Portfolio Table 98. Eli Lilly And Company Recent Development Table 99. Allergan Company Information Table 100. Allergan Business Overview Table 101. Allergan Women’s Health Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Allergan Women’s Health Drugs Product Portfolio Table 103. Allergan Recent Development Table 104. Agile Therapeutics Inc Company Information Table 105. Agile Therapeutics Inc Business Overview Table 106. Agile Therapeutics Inc Women’s Health Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Agile Therapeutics Inc Women’s Health Drugs Product Portfolio Table 108. Agile Therapeutics Inc Recent Development Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Women’s Health Drugs Product Image Figure 2. Global Women’s Health Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Women’s Health Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Women’s Health Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Minastrin 24 Fe Image Figure 8. XGEVA Image Figure 9. Prolia Image Figure 10. Mirena Image Figure 11. EVISTA Image Figure 12. Zometa Image Figure 13. Reclast/Aclasta Image Figure 14. Others (Premarin, ACTONEL, ORTHO TRI-CY LO) Image Figure 15. Global Women’s Health Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Women’s Health Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Women’s Health Drugs Sales Value Share by Type (2021-2032) Figure 18. Contraceptives Image Figure 19. Polycystic Ovary Syndrome Image Figure 20. Hormonal Infertility Image Figure 21. Menopause Image Figure 22. Postmenopausal Osteoporosis Image Figure 23. Endometriosis Image Figure 24. Other Applications Image Figure 25. Global Women’s Health Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Women’s Health Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Women’s Health Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Women’s Health Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Women’s Health Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Women’s Health Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Women’s Health Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Women’s Health Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Women’s Health Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Women’s Health Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Women’s Health Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Women’s Health Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Women’s Health Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Women’s Health Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Women’s Health Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Women’s Health Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Years Considered Figure 125. Research Process Figure 126. Key Executives Interviewed

Scope & coverage.

Types
  • Minastrin 24 Fe
  • XGEVA
  • Prolia
  • Mirena
  • EVISTA
  • Zometa
  • Reclast/Aclasta
  • Others (Premarin, ACTONEL, ORTHO TRI-CY LO)
Applications
  • Contraceptives
  • Polycystic Ovary Syndrome
  • Hormonal Infertility
  • Menopause
  • Postmenopausal Osteoporosis
  • Endometriosis
  • Other Applications
Companies covered
  • Johnson & Johnson
  • Novartis AG
  • Merck & Co
  • Mylan N.V.
  • Pfizer Inc
  • Bayer AG
  • Amgen
  • Lupin (India)
  • Ferring Pharmaceuticals
  • Eli Lilly And Company
  • Allergan
  • Agile Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Women’s Health Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Women’s Health Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Women’s Health Drugs Market Dynamics
  1. 2.1 Women’s Health Drugs Industry Trends
  2. 2.2 Women’s Health Drugs Industry Drivers
  3. 2.3 Women’s Health Drugs Industry Opportunities and Challenges
  4. 2.4 Women’s Health Drugs Industry Restraints
3 Women’s Health Drugs Market by Company
  1. 3.1 Global Women’s Health Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Women’s Health Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Women’s Health Drugs Company Ranking (2024-2026)
  4. 3.4 Global Women’s Health Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Women’s Health Drugs Company Product Type and Application
  6. 3.6 Global Women’s Health Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Women’s Health Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Women’s Health Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Women’s Health Drugs Market by Type
  1. 4.1 Women’s Health Drugs Type Introduction
  2. 4.1.1 Minastrin 24 Fe
  3. 4.1.2 XGEVA
  4. 4.1.3 Prolia
  5. 4.1.4 Mirena
  6. 4.1.5 EVISTA
  7. 4.1.6 Zometa
  8. 4.1.7 Reclast/Aclasta
  9. 4.1.8 Others (Premarin, ACTONEL, ORTHO TRI-CY LO)
  10. 4.2 Global Women’s Health Drugs Sales Value by Type
  11. 4.2.1 Global Women’s Health Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Women’s Health Drugs Sales Value by Type (2021-2032)
  13. 4.2.3 Global Women’s Health Drugs Sales Value Share by Type (2021-2032)
5 Women’s Health Drugs Market by Application
  1. 5.1 Women’s Health Drugs Application Introduction
  2. 5.1.1 Contraceptives
  3. 5.1.2 Polycystic Ovary Syndrome
  4. 5.1.3 Hormonal Infertility
  5. 5.1.4 Menopause
  6. 5.1.5 Postmenopausal Osteoporosis
  7. 5.1.6 Endometriosis
  8. 5.1.7 Other Applications
  9. 5.2 Global Women’s Health Drugs Sales Value by Application
  10. 5.2.1 Global Women’s Health Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global Women’s Health Drugs Sales Value by Application (2021-2032)
  12. 5.2.3 Global Women’s Health Drugs Sales Value Share by Application (2021-2032)
6 Women’s Health Drugs Regional Value Analysis
  1. 6.1 Global Women’s Health Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Women’s Health Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Women’s Health Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Women’s Health Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Women’s Health Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Women’s Health Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Women’s Health Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Women’s Health Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Women’s Health Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Women’s Health Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Women’s Health Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Women’s Health Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Women’s Health Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Women’s Health Drugs Sales Value Share by Country, 2025 VS 2032
7 Women’s Health Drugs Country-level Value Analysis
  1. 7.1 Global Women’s Health Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Women’s Health Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Women’s Health Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Women’s Health Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Women’s Health Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Women’s Health Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Women’s Health Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Women’s Health Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Women’s Health Drugs Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Women’s Health Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Women’s Health Drugs Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Merck & Co
  14. 8.3.1 Merck & Co Company Information
  15. 8.3.2 Merck & Co Business Overview
  16. 8.3.3 Merck & Co Women’s Health Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co Women’s Health Drugs Product Portfolio
  18. 8.3.5 Merck & Co Recent Developments
  19. 8.4 Mylan N.V.
  20. 8.4.1 Mylan N.V. Company Information
  21. 8.4.2 Mylan N.V. Business Overview
  22. 8.4.3 Mylan N.V. Women’s Health Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan N.V. Women’s Health Drugs Product Portfolio
  24. 8.4.5 Mylan N.V. Recent Developments
  25. 8.5 Pfizer Inc
  26. 8.5.1 Pfizer Inc Company Information
  27. 8.5.2 Pfizer Inc Business Overview
  28. 8.5.3 Pfizer Inc Women’s Health Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Inc Women’s Health Drugs Product Portfolio
  30. 8.5.5 Pfizer Inc Recent Developments
  31. 8.6 Bayer AG
  32. 8.6.1 Bayer AG Company Information
  33. 8.6.2 Bayer AG Business Overview
  34. 8.6.3 Bayer AG Women’s Health Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer AG Women’s Health Drugs Product Portfolio
  36. 8.6.5 Bayer AG Recent Developments
  37. 8.7 Amgen
  38. 8.7.1 Amgen Company Information
  39. 8.7.2 Amgen Business Overview
  40. 8.7.3 Amgen Women’s Health Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Amgen Women’s Health Drugs Product Portfolio
  42. 8.7.5 Amgen Recent Developments
  43. 8.8 Lupin (India)
  44. 8.8.1 Lupin (India) Company Information
  45. 8.8.2 Lupin (India) Business Overview
  46. 8.8.3 Lupin (India) Women’s Health Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lupin (India) Women’s Health Drugs Product Portfolio
  48. 8.8.5 Lupin (India) Recent Developments
  49. 8.9 Ferring Pharmaceuticals
  50. 8.9.1 Ferring Pharmaceuticals Company Information
  51. 8.9.2 Ferring Pharmaceuticals Business Overview
  52. 8.9.3 Ferring Pharmaceuticals Women’s Health Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ferring Pharmaceuticals Women’s Health Drugs Product Portfolio
  54. 8.9.5 Ferring Pharmaceuticals Recent Developments
  55. 8.10 Eli Lilly And Company
  56. 8.10.1 Eli Lilly And Company Company Information
  57. 8.10.2 Eli Lilly And Company Business Overview
  58. 8.10.3 Eli Lilly And Company Women’s Health Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly And Company Women’s Health Drugs Product Portfolio
  60. 8.10.5 Eli Lilly And Company Recent Developments
  61. 8.11 Allergan
  62. 8.11.1 Allergan Company Information
  63. 8.11.2 Allergan Business Overview
  64. 8.11.3 Allergan Women’s Health Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Allergan Women’s Health Drugs Product Portfolio
  66. 8.11.5 Allergan Recent Developments
  67. 8.12 Agile Therapeutics Inc
  68. 8.12.1 Agile Therapeutics Inc Company Information
  69. 8.12.2 Agile Therapeutics Inc Business Overview
  70. 8.12.3 Agile Therapeutics Inc Women’s Health Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Agile Therapeutics Inc Women’s Health Drugs Product Portfolio
  72. 8.12.5 Agile Therapeutics Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst